期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

咪喹莫特的临床应用和市场分析 被引量：6

Progress of lmiquimod in Clinical Application and Market Analysis
暂未订购
导出
摘要 咪喹莫特是一种人工合成的非核苷类异环胺类外用免疫调节剂,可诱导细胞产生多种细胞因子,发挥抗病毒和抗肿瘤活性。广泛用于治疗尖锐湿疣、光化性角化病、基底细胞癌等多种皮肤科疾病。因其具有独特的免疫调节机制,适应症范围也在不断扩大,本文从药效学特征、临床应用和市场信息等方面进行了综述。 Imiquimod is an immune response modulator that can induce cells to produce a variety of cytokines to play antiviral and antitumor activities.It is indicated for the widely treatment of extemal anogenital warts, superficial basal cell carcinoma,actinic keratoses and various skin lesions. Because of its unique mechanism of immune regulation, there is a growing evidence for its effectiveness in treating a variety of other skin conditions. This review mainly examines the pharmacodynamic profile, clinical application and market information of imiquimod.
作者 武英
机构地区 中国医药集团总公司四川抗菌素工业研究所
出处 《国外医药（抗生素分册）》 CAS 2012年第2期76-82,共7页 World Notes on Antibiotics
关键词 咪喹莫特 免疫调节 临床应用 市场 imiquimod immune regulation clinical application market
分类号 R979.5 [医药卫生—药品]
  • 相关文献

参考文献50

  • 1Sch6n M, Sch6n MP. The antitumoral mode of action of imiquimod and other imidazoquinolines[J], Curr Med Chem, 2007, 14 (6): 681.
  • 2Miller RL, Tomai MA, Harrison C J, et Immunomodulation as a treatment strat for genitalherpes:r Immunopharmacol, 200 eview of the evidence[J] 2, 2:443 al. egy .Int.
  • 3Suzuki H, Wang B, Shivji GM, etal. Imiquimod,atop icalimmuneresponse modifier, induces migration of Langerhanscells[J]. J Invest Dermatol, 2000, 114:135.
  • 4Syed TA. A review of the applications of imiquimod:a novel immune response modifier[J].Expert Opin Pharmacother, 2001, 2:877.
  • 5Pasmatzi ES, Chaidaroglou A, Sakkis T, et al. Short- term topical application of imiquimod induces systemic immunomodulation in healthy individuals [J]. J Immunother, 2006, 29 (6): 668.
  • 6Anonymous Imiquimod for genital warts[J]. Med Lett Drugs Ther, 1997, 39:118.
  • 73M Pharmaceuticals. Aldara TM (imiquimod)cream,5% (package insert), 2004.
  • 8Kawashima M, Uchida N, Nogita T. Evaluation of skinirritability and safety of imiquimod 5% cream in 7-day repeated application among healthy volunteers [J]. J Clin Ther Med, 2007, 23 (5): 363.
  • 9Kaidbey K, Owens M, Liberda M, et al. Safety studies of topical imiquimod 5% cream on normal skin exposed to ultraviolet radiation[J]. Toxicology, 2002, 2, 178 (2): 175.
  • 10Thatcher TH, Luzina I, Fishelevich R, et al imiquimod treatment prevents UV-light induced contact hypersensitivity and immune tolerance[J] Dermatol, 2006, 126 (4): 821 Topical loss of J Invest.

二级参考文献13

  • 1Schlosser KA. Infantile hemangioma: how to treat this benign neoplasm of childhood. JAAPA, 2009,22 (5) :46-49.
  • 2Schwartz RA, Sidor MI, Musumeci ML, et al. Infantile haemangiomas: a challenge in paediatric dermatology. J Eur Acad Dermatol Venereol, 2010,24(6) :631-638.
  • 3Pandey A, Gangopadhyay AN, Gopal SC, et al. Twenty years' experience of steroids in infantile hemangioma--a developing country perspective. J Ped Surg, 2009,44(4) :688-694.
  • 4Zimmermann AP, Wiegand S, Werner JA, et al. Propranolol therapy for infantile haemangiomas: review of the literature. Int J Pediatr Otorhinolaryngol, 2010,74(4) :338-342.
  • 5Martinez MI, Sanchez-Carpintero I, North PE, et al. Infantile hemangioma: clinical resolution with 5% imiquimod cream. Arch Dermatol,2002,138 (7) :881-884.
  • 6Welsh O, Olazaran Z, Gomez M, et al. Treatment of infantile haemangiomas with short term appllcation of imiquimod 5% cream. J Am Acad Dermatol, 2004,51 (4) :639-642.
  • 7Hazen PG, Carney JF, Engstrom CW, et al. Proliferating haemangioma of infancy: successful treatment with topical 5% imiquimod cream. Pediatr Dermatol, 2005, 22 (3) : 254-256.
  • 8Senchak AJ, Dann M, Cable B, et al. Successful treatment of cutaneous hemangioma of infancy with topical imiquimod 5% : a report of 3 cases. Ear Nose Throat J, 2010,89(3) :E21-25.
  • 9Ritter MR, Moreno SK, Dorrell MI, et al. Identifying potential regulators of infantile hemangioma progression through large-scale expression analysis: a possible role for the immune system and indoleamine 2,3 dioxygenase (IDO) during involution. Lymphat Res Biol, 2003,1(4) :291-299.
  • 10North PE, Waner M, Mizeracki A, et al. A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol, 2001,137 (5) :559-570.

共引文献11

同被引文献58

引证文献6

二级引证文献24

国外医药（抗生素分册）
2012年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部